GERMANY – Implandata Ophthalmic Products, a digital health eye care company, has been named a top 12 health techpreneur at the Medica Healthcare Innovation World Cup, the world’s largest medical trade fair.
Implandata was named a leading breakthrough health care innovator among more than 300 competitors and has been invited to present its disruptive Eyemate solution at the Medica Connected Health Care Forum on November 15th, 2021.
Earlier in 2021, the US FDA granted Breakthrough Device Designation. The system allows patients to self-measure critical disease parameters and then automatically sends the data to their eye doctors in real time.
Earlier in 2021, the US FDA granted Breakthrough Device Designation. The system allows patients to self-measure critical disease parameters and then automatically sends the data to their eye doctors in real time.
This data allows eye doctors to obtain timely information about therapy effectiveness and to remotely adjust treatment based on a patient’s current condition, rather than making therapeutic adjustments based on infrequent office visits.
Glaucoma is an age-related chronic eye disease in which elevated intraocular pressure causes irreversible damage to the optic nerve, resulting in progressive loss of vision and, in severe cases, blindness.
Because disease status and the effectiveness of eye pressure lowering therapy between office visits are unknown, the current practice of seeing patients in 2-4 office visits per year is insufficient to prevent loss of sight for many patients.
Despite a plethora of treatment options, ineffective therapies and disease progression result in avoidable vision loss in a significant number of patients.
Implandata’s proprietary EYEMATE system is the world’s only clinically validated and CE marked remote glaucoma care product.
This device works in tandem with the ground-breaking EYEMATE system to provide digitally enabled remote glaucoma monitoring and management.
Implandata’s CE-certified product enables ophthalmologists to detect increased intra-ocular pressure (IOP) and manage the patient’s condition more effectively, reducing the risk of post-surgical complications and associated vision loss.
This is especially important given that keratoprosthesis, an infrequent yet important procedure for restoring vision, is performed on patients whose donor cornea transplantation procedure has failed or shows only limited success.
Keratoprosthesis patients are typically younger people for whom vision preservation is extremely important and costly.
In such cases, Implandata’s proprietary EYEMATE eye pressure sensor is implanted in conjunction with the keratoprosthesis procedure, allowing for continuous monitoring of the eye pressure.
The CE-marked EYEMATE system is in use at leading eye centers in Europe. The company anticipates to approach the untouched huge market opportunities in North America and China in the very near future.
Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE
